Table 3

Differences between patients with active IBD and IBD in remission

Active IBDIBD in remissionP value
Age (mean in years (SD))42 (16)40 (17)0.29
Female gender (n (%))69 (44)87 (56)0.9
Body mass index (mean in kg (SD))82.4 (24)77.9 (18)0.09
Crohn’s disease (vs ulcerative colitis) (n (%))78 (41)112 (59)0.07
Disease duration (mean in years (SD))10.9 (9.5)11.9 (9.8)0.44
Trough levels of Infliximab (median (IQR))5.7 (0–14.1)11.1 (4.7–26.9)0.0004*
Detectable anti-infliximab antibody (n (%))27 (75)9 (25)<0.0001*
Time on infliximab (median in months (IQR))13 (7–22)17 (8–45)0.04*
Combination therapy with an immunomodulator (n (%))66 (55.5)78 (52.7)0.65
SIBDQ (median (IQR))45 (13.5)54 (12.7)<0.0001*
Albumin (mean in mg/dL (SD))4.1 (0.43)4.3 (0.36)0.0003*
  • (1) Only patients with Crohn’s disease (2) Only patients with ulcerative colitis.

  • *Statistically significant.

  • IBD, inflammatory bowel disease; SIBDQ, Short Inflammatory Bowel Diseases Questionnaire.